Literature DB >> 2308907

Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs.

S Henricsson1, A Lindholm, M Aravoglou.   

Abstract

The metabolism of cyclosporin was studied in human liver microsomes. There was no metabolism in the presence of cytochrome C or carbon monoxide or in the absence of cofactors, suggesting metabolism by cytochrome P-450 enzymes. The metabolism was inhibited by ketoconazole and erythromycin, by the steroids methylprednisolone and oestradiol, and by the calcium antagonists diltiazem, nifedipine, prenylamine and verapamil. These in vitro findings correlate well with previously published clinical reports suggesting that these drugs may inhibit the metabolism of cyclosporin in vivo. Our observations suggest that metabolic interactions between cyclosporin and other drugs in vivo may be predicted in vitro under proper experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308907     DOI: 10.1111/j.1600-0773.1990.tb00701.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.

Authors:  E S Guns; P L Bullock; M L Reimer; R Dixon; M Bally; L D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4.

Authors:  P A Kelly; H Wang; K L Napoli; B D Kahan; H W Strobel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

5.  Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.

Authors:  Emma S Guns; Tetyana Denyssevych; Ross Dixon; Marcel B Bally; Lawrence Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Apr-Jun       Impact factor: 2.569

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.